In a recent interview at the SNMMI conference, Krishna Patel, M.D., discussed the benefits of the PET perfusion radiotracer agent 18F-flurpiridaz and new research findings showing the agent’s increased sensitivity and specificity in diagnosing coronary artery disease in obese patients.
The use of conventional imaging for diagnosing coronary artery disease (CAD) in obese patients can be challenging. Attenuation artifacts can be problematic with single photon emission computed tomography (SPECT) and a lack of crisp image quality is an issue with coronary computed tomography angiography (CCTA) in this patient population, pointed out Krishna Patel, MD, in an interview at the recent Society for Nuclear Medicine and Molecular Imaging (SNMMI) conference.
Higher radiation dosing is also a concern with both of the aforementioned modalities, noted Dr. Patel, an assistant professor of medicine (cardiology) and population health science and policy at Icahn School of Medicine at Mount Sinai.
Accordingly, Dr. Patel and colleagues examined the use of the positron emission tomography (PET) perfusion radiotracer agent 18F-flurpiridaz in comparison to 99mTc-SPECT for detecting CAD in a subgroup analysis involving 298 obese patients (mean age of 62.1) from a phase 3 trial.
The researchers found that among obese patients, 18F-flurpiridaz demonstrated higher sensitivity rates (76.9 percent versus 69.2 percent) and specificity rates (66.9 percent versus 61.9 percent) in comparison to 99mTc-SPECT. The use of 18F-flurpiridaz also reduced radiation exposure by one-third (6.2 mSv PET) in comparison to tetrofosmin SPECT (9.9 mSv) and by one-half in comparison to sestamibi SPECT (12.4 mSv), according to Dr. Patel and colleagues.
Dr. Patel, the director of cardiac PET at Mount Sinai Morningside in New York City, added that other key benefits of 18F-flurpiridaz include a longer half-life (110 minutes) than other PET perfusion tracer agents and unit dose availability, factors that may significantly expand access to stress cardiac PET myocardial perfusion imaging.
For more insights from Dr. Patel, watch the video below.
Can Abbreviated Breast MRI Have an Impact in Assessing Post-Neoadjuvant Chemotherapy Response?
April 24th 2025New research presented at the Society for Breast Imaging (SBI) conference suggests that abbreviated MRI is comparable to full MRI in assessing pathologic complete response to neoadjuvant chemotherapy for breast cancer.
What New Research Reveals About Novice Use of AI-Guided Cardiac Ultrasound
April 4th 2025In a study recently presented at the American College of Cardiology (ACC) conference, researchers found that novice use of AI-guided cardiac ultrasound after an AI-enabled electrocardiogram increased the positive predictive value for reduced left ventricular ejection fraction (LVEF) or aortic valve stenosis by 33 percent.
GE HealthCare Debuts AI-Powered Cardiac CT Device at ACC Conference
April 1st 2025Featuring enhanced low-dose image quality with motion-free images, the Revolution Vibe CT system reportedly facilitates improved diagnostic clarity for patients with conditions ranging from in-stent restenosis to atrial fibrillation.
New AI-Enabled Portable Ultrasound May Facilitate 50 Percent Reduction in Cardiac Imaging Scan Time
March 28th 2025Artificial intelligence (AI)-powered measurement capabilities provide key features with the Compact Ultrasound 5500CV device, which was unveiled at the American College of Cardiology (ACC) conference.
GE HealthCare Launches PET MPI Agent Flyrcado at ACC Conference
March 28th 2025The positron emission tomography myocardial perfusion imaging (PET MPI) agent, which offers a significantly higher half-life than other cardiac PET agents, was recently granted pass-through payment status by CMS that will go into effect on April 1, 2025.